|
?:authorAffiliation
|
-
[\'Biostatistics and Research Decision Sciences, Merck & Co., North Wales, Pennsylvania (D.V.M., J.H.).\', \'Fred Hutchinson Cancer Research Center, Seattle, Washington (H.E.J., L.N.C., D.D., Y.F., Y.H., Y.H., O.H., M.J.).\', \'Fred Hutchinson Cancer Research Center and University of Washington, Seattle, Washington (T.R.F., E.R.B., M.C., L.C., P.B.G.).\', \'Vaccines Clinical Research, Merck & Co., Kenilworth, New Jersey (P.W.A.).\', \'University of Maryland School of Medicine, Baltimore, Maryland (K.M.N.).\', \'Rollins School of Public Health, Emory University, Atlanta, Georgia (D.B.).\', \'Novavax, Gaithersburg, Maryland (I.C.).\', \'National Institute of Allergy and Infectious Diseases, Bethesda, Maryland (M.P.F., M.N., D.F.).\', \'Moderna, Cambridge, Massachusetts (S.H., H.Z.).\', \'AstraZeneca, Cambridge, United Kingdom (I.H.).\', \'University of Washington, Seattle, Washington (A.L.).\', \'Janssen Pharmaceuticals, Beerse, Belgium (A.V.).\', \'Institute for Global Health and Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina (M.S.C.).\']
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}